Timing note: TMO’s 2Q26 earnings call is today, Thursday, July 23, 2026, not tomorrow. The company is scheduled to report before the market opens and host its call at 8:30 a.m. ET.
Thermo Fisher enters 2Q with a relatively well-defined company guide, but a higher bar around the credibility of the second-half acceleration embedded in its full-year outlook. Management’s Q1 message was constructive: core end markets were tracking to plan, biopharma demand was improving, and the company raised 2026 guidance following the Clario acquisition and better-than-expected operating execution.
For 2Q, the key issue is whether TMO can demonstrate that Q1’s 1% organic growth was a temporary low point—affected by one fewer selling day and pharma-services revenue timing—and that the expected step-up to roughly 3% organic growth is occurring. A clean result would pair that growth progression with durable productivity, continued momentum in clinical research and bioproduction, and no meaningful deterioration in academic/government, China, or diagnostics.
The stock closed at $526.50 on July 22, up roughly 2.4% from the close before the April Q1 report but about 3.1% below its July 16 closing high. That suggests some recovery in expectations, but investors are likely still focused on proof that the company can achieve its stated 2026–27 growth progression.
At Q1 earnings, management guided to:
| Metric | 2Q26 framework |
|---|---|
| Organic revenue growth | ~3% |
| Adjusted EPS | $5.69–$5.74 |
| Implied adjusted EPS growth vs. 2Q25 | ~6%–7% |
| 2Q25 adjusted EPS comparison | $5.36 |
The EPS range is derived from management’s statement that 2Q adjusted EPS should be $0.25–$0.30 above Q1’s $5.44.
This is a reasonable but important test. Last year’s 2Q had only 2% organic growth and adjusted EPS of $5.36, while margins were pressured by mix and operating costs. TMO’s 2Q26 framework calls for a more visible growth step-up without sacrificing the productivity and margin discipline that have supported the earnings algorithm.
TMO’s Q1 organic growth of 1% understated the underlying run rate. Management identified approximately:
That implies a more normalized Q1 organic-growth rate nearer 3%, broadly consistent with the 2Q outlook. Management also emphasized that the expected 2026 progression does not require a large improvement in underlying macro conditions; it is substantially driven by calendar effects, comparisons, and the timing of contracted pharma-services work.
The more favorable 2Q comparison in Analytical Instruments is particularly important. Q1 Analytical Instruments organic revenue declined 2%, with muted U.S. and China academic/government demand and a difficult tariff-related comparison. If that segment stabilizes as expected, the consolidated growth bridge becomes much easier to believe.
The risk is that the anticipated improvement is more dependent on a real recovery in end-market demand than management has indicated. Investors will be looking for evidence that:
A result near guidance accompanied by more cautious commentary around these areas could be treated poorly, particularly because the full-year outlook requires a stronger second half.
After Q1, TMO raised 2026 guidance to:
| 2026 guidance | Range | Midpoint |
|---|---|---|
| Revenue | $47.3B–$48.1B | $47.7B |
| Organic revenue growth | 3%–4% | Slightly above 3% |
| Adjusted EPS | $24.64–$25.12 | $24.88 |
| Adjusted operating-margin expansion | ~70 bps | — |
| Free cash flow | $6.9B–$7.4B | $7.15B |
The guide incorporates Clario, which management expects to contribute approximately $900 million of 2026 revenue and $0.32 of adjusted EPS, net of financing costs. That makes the organic-growth trajectory particularly important: investors will want to separate reported growth from acquired growth and assess whether the legacy franchise is accelerating as planned.
After Q1 actual adjusted EPS of $5.44 and the 2Q guide of $5.69–$5.74, TMO needs approximately $13.51–$13.94 of adjusted EPS in the second half to achieve the full-year range. That is not necessarily alarming—TMO has meaningful second-half seasonality—but it raises the importance of management reaffirming the ramp in pharma services, bioproduction, and broader biopharma demand.
This is TMO’s largest segment and the most important driver of the 2026 recovery narrative.
What worked in Q1 - 4% organic growth. - Strong clinical-research performance, including authorizations growth. - Continued share gains in research and safety-market channels. - Clario was added to the segment late in Q1.
What matters in 2Q - Clinical-research bookings/authorizations and pipeline trends. - Revenue conversion in pharma services. - Any evidence that biotech funding is reaching discovery, lab-supply, and development spending. - Early Clario integration progress and customer reception. - Margin performance, given ongoing investment and acquisition mix.
The bull case is that TMO’s integrated CRO/CDMO model, now supplemented by Clario’s endpoint-data capabilities, gains share as biotech and pharma customers seek faster and less fragmented drug-development workflows.
Life Sciences Solutions grew 1% organically in Q1, with bioproduction described as a standout. The business is strategically important because it is positioned to benefit from biologics growth, biomanufacturing capacity expansion, and eventual U.S. reshoring investments.
Investors should focus on: - The durability of bioproduction growth. - Integration and growth of the acquired Solventum filtration and separation business. - Progress on customer wins tied to U.S. manufacturing expansion. - The pace at which those wins turn into near-term revenue versus 2027–28 opportunities.
Management has characterized filtration as a mid- to high-single-digit organic-growth opportunity under Thermo Fisher ownership. Confirmation of that trajectory would support the long-term strategic case.
Analytical Instruments was the weak point in Q1:
The 2Q setup is more favorable because comparisons ease, but the market will want more than an easier comp. Key indicators include: - Order trends in chromatography, mass spectrometry, cryo-EM, and semiconductor-related electron microscopy. - Whether U.S. academic/government funding flows are improving. - China demand and whether pharma/biotech strength is offsetting continued academic weakness. - The degree to which tariffs, mix, and foreign exchange continue to pressure margin.
A stabilization here would materially improve confidence in the company-wide organic-growth guide. Continued weakness could keep investors skeptical of the second-half outlook.
Specialty Diagnostics declined 3% organically in Q1, influenced by one fewer selling day and a difficult respiratory comparison. Transplant diagnostics remained a source of strength.
For 2Q, watch: - Whether the expected normalization after the Q1 day-count and respiratory effects occurs. - Performance in immunodiagnostics and microbiology-related end markets. - Margin preservation, particularly if volume remains soft.
This segment is unlikely to determine the quarter on its own, but it can affect the quality of the consolidated earnings result.
TMO’s Q1 adjusted operating margin was 21.8%, down 10 bps year over year despite strong productivity. Management cited approximately 80 bps of tariff and related-FX pressure in the quarter. For the full year, however, it still guides to approximately 70 bps of margin expansion, including only about a 30-bp year-over-year tariff/FX headwind.
The implication is that productivity, pricing, mix, and acquisition contributions must more than offset external costs through the remainder of the year.
Key questions for the call:
A guide raise would be positive, but a reaffirmation with stronger confidence on margin conversion could be nearly as important.
TMO completed the approximately $9 billion Clario acquisition in late March, funded in part with new debt. At the end of Q1, gross leverage was 3.8x adjusted EBITDA and net leverage was 3.5x. The acquisition is strategically compelling, but investors will want evidence that integration is proceeding smoothly and that the company remains on track for its stated return targets.
Also notable: TMO announced plans to divest its microbiology business for approximately $1.1 billion, with an expected second-half close. Management indicated it would address the 2026 financial impact on the Q2 call. This is an important item to watch because it could affect reported revenue, mix, capital deployment, and the presentation of the remaining Diagnostics portfolio.
TMO’s 2Q report is principally a proof-of-progression quarter. The company does not need a dramatic end-market recovery to support its framework, but it does need to show that Q1 was the trough in organic growth and that its biopharma-led acceleration is tangible.
The most important datapoints will be: organic growth versus the ~3% target; clinical research and pharma-services momentum; stabilization in Analytical Instruments; margin resilience amid tariffs; and the degree of confidence behind the full-year guide. A clean execution quarter with maintained or improved guidance should reinforce the view that Thermo Fisher’s differentiated portfolio, productivity system, and recent acquisitions can support a stronger second half and a more durable 2027 growth setup.